Valbenazine improves chorea associated with Huntington's dis

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.

Related Keywords

United States , American , Lily Ramsey , Neurocrine Biosciences , Furr Stimming , Erin Furr Stimming , Drug Administration , Huntington Disease Health Index , Huntington Disease Society Of America Center , Clinical Research Inc , Mcgovern Medical School , American Academy Of Neurology , Huntington Study Group , Clinical Trials Coordination Center , University Of Rochester Medical Center , Lancet Neurology , Memorial Hermann Chair , American Academy , Disease Society , America Center , Disease Health Index , New Drug Application , Rochester Medical Center , Chorea , Efficacy , Huntington 39s Disease , Medical School , Movement Disorder , Eurology , Placebo ,